Adjuvant docetaxel for node-positive breast cancer.

M, Martin; T, Pienkowski; J, Mackey; M, Pawlicki; JP, Guastalla; C, Weaver; E, Tomiak; T, Al-Tweigeri; L, Chap; E, Juhos; R, Guevin; A, Howell; T, Fornander; J, Hainsworth; R, Coleman; J, Vinholes; M, Modiano; T, Pinter; SC, Tang; B, Colwell; C, Prady; L, Provencher; D, Walde; A, Rodriguez-Lescure; J, Hugh; C, Loret; M, Rupin; S, Blitz; P, Jacobs; M, Murawsky; A, Riva; C, Vogel

doi:10.1056/nejmoa043681

Public

Adjuvant docetaxel for node-positive breast cancer.

Shared by NobleBlocks on Jun 1, 2005 • 12:00 AM UTC

Authors:

Martin M

Pienkowski T

Mackey J

Abstract

Background We compared docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) as adjuvant chemotherapy for operable node-positive breast cancer.Methods We randomly assigned 1491 women with axillary node-positive breast cancer to six cycles...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!